These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38014919)
1. LSD1 in drug discovery: From biological function to clinical application. Liu HM; Zhou Y; Chen HX; Wu JW; Ji SK; Shen L; Wang SP; Liu HM; Liu Y; Dai XJ; Zheng YC Med Res Rev; 2024 Mar; 44(2):833-866. PubMed ID: 38014919 [TBL] [Abstract][Full Text] [Related]
2. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1. Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958 [TBL] [Abstract][Full Text] [Related]
3. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy. Chen Y; Jie W; Yan W; Zhou K; Xiao Y Crit Rev Eukaryot Gene Expr; 2012; 22(1):53-9. PubMed ID: 22339659 [TBL] [Abstract][Full Text] [Related]
4. Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1. Zhou C; Wu F; Lu L; Wei L; Pai E; Yao Y; Song Y PLoS One; 2017; 12(2):e0170301. PubMed ID: 28158205 [TBL] [Abstract][Full Text] [Related]
5. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment. Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896 [TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors. Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136 [TBL] [Abstract][Full Text] [Related]
8. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860 [TBL] [Abstract][Full Text] [Related]
9. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Schmidt DM; McCafferty DG Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163 [TBL] [Abstract][Full Text] [Related]
10. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening. Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512 [TBL] [Abstract][Full Text] [Related]
11. T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice. Matsuda S; Baba R; Oki H; Morimoto S; Toyofuku M; Igaki S; Kamada Y; Iwasaki S; Matsumiya K; Hibino R; Kamada H; Hirakawa T; Iwatani M; Tsuchida K; Hara R; Ito M; Kimura H Neuropsychopharmacology; 2019 Jul; 44(8):1505-1512. PubMed ID: 30580376 [TBL] [Abstract][Full Text] [Related]
12. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509 [TBL] [Abstract][Full Text] [Related]
13. Promising natural lysine specific demethylase 1 inhibitors for cancer treatment: advances and outlooks. Li ZR; Gu MZ; Xu X; Zhang JH; Zhang HL; Han C Chin J Nat Med; 2022 Apr; 20(4):241-257. PubMed ID: 35487595 [TBL] [Abstract][Full Text] [Related]
15. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020). Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202 [TBL] [Abstract][Full Text] [Related]
16. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective. Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269 [TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking. Zhou C; Kang D; Xu Y; Zhang L; Zha X Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381 [TBL] [Abstract][Full Text] [Related]
18. 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1. Wu F; Zhou C; Yao Y; Wei L; Feng Z; Deng L; Song Y J Med Chem; 2016 Jan; 59(1):253-263. PubMed ID: 26652247 [TBL] [Abstract][Full Text] [Related]
19. Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes. El Mansouri FE; Nebbaki SS; Kapoor M; Afif H; Martel-Pelletier J; Pelletier JP; Benderdour M; Fahmi H Arthritis Res Ther; 2014 May; 16(3):R113. PubMed ID: 24886859 [TBL] [Abstract][Full Text] [Related]
20. Natural products as LSD1 inhibitors for cancer therapy. Fang Y; Yang C; Yu Z; Li X; Mu Q; Liao G; Yu B Acta Pharm Sin B; 2020 Jun; 11(3):621-31. PubMed ID: 32837872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]